These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

546 related articles for article (PubMed ID: 31811017)

  • 1. Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin Lymphoma.
    Chen R; Herrera AF; Hou J; Chen L; Wu J; Guo Y; Synold TW; Ngo VN; Puverel S; Mei M; Popplewell L; Yi S; Song JY; Tao S; Wu X; Chan WC; Forman SJ; Kwak LW; Rosen ST; Newman EM
    Clin Cancer Res; 2020 Mar; 26(5):1034-1044. PubMed ID: 31811017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin.
    Chen R; Hou J; Newman E; Kim Y; Donohue C; Liu X; Thomas SH; Forman SJ; Kane SE
    Mol Cancer Ther; 2015 Jun; 14(6):1376-84. PubMed ID: 25840583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
    Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F
    Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study.
    Lynch RC; Cassaday RD; Smith SD; Fromm JR; Cowan AJ; Warren EH; Shadman MS; Shustov A; Till BG; Ujjani CS; Libby EN; Philip M; Coye H; Martino CN; Bhark SL; Morris K; Rasmussen H; Behnia S; Voutsinas J; Gopal AK
    Lancet Haematol; 2021 Aug; 8(8):e562-e571. PubMed ID: 34329577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.
    Kuruvilla J; Ramchandren R; Santoro A; Paszkiewicz-Kozik E; Gasiorowski R; Johnson NA; Fogliatto LM; Goncalves I; de Oliveira JSR; Buccheri V; Perini GF; Goldschmidt N; Kriachok I; Dickinson M; Komarnicki M; McDonald A; Ozcan M; Sekiguchi N; Zhu Y; Nahar A; Marinello P; Zinzani PL;
    Lancet Oncol; 2021 Apr; 22(4):512-524. PubMed ID: 33721562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single-arm, phase 1-2 trial.
    Cole PD; McCarten KM; Pei Q; Spira M; Metzger ML; Drachtman RA; Horton TM; Bush R; Blaney SM; Weigel BJ; Kelly KM
    Lancet Oncol; 2018 Sep; 19(9):1229-1238. PubMed ID: 30122620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial.
    Diefenbach CS; Hong F; Ambinder RF; Cohen JB; Robertson MJ; David KA; Advani RH; Fenske TS; Barta SK; Palmisiano ND; Svoboda J; Morgan DS; Karmali R; Sharon E; Streicher H; Kahl BS; Ansell SM
    Lancet Haematol; 2020 Sep; 7(9):e660-e670. PubMed ID: 32853585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30+ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program.
    Perrot A; Monjanel H; Bouabdallah R; Quittet P; Sarkozy C; Bernard M; Stamatoullas A; Borel C; Bouabdallah K; Nicolas-Virelizier E; Fournier M; Morschhauser F; Brice P;
    Haematologica; 2016 Apr; 101(4):466-73. PubMed ID: 26768687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brentuximab vedotin for relapsed or refractory Hodgkin's lymphoma.
    Chen R; Chen B
    Drug Des Devel Ther; 2015; 9():1729-33. PubMed ID: 25848209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A20 and RBX1 Regulate Brentuximab Vedotin Sensitivity in Hodgkin Lymphoma Models.
    Wei W; Lin Y; Song Z; Xiao W; Chen L; Yin J; Zhou Y; Barta SK; Petrus M; Waldmann TA; Yang Y
    Clin Cancer Res; 2020 Aug; 26(15):4093-4106. PubMed ID: 32299816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brentuximab vedotin in transplant-naive patients with relapsed or refractory hodgkin lymphoma: analysis of two phase I studies.
    Forero-Torres A; Fanale M; Advani R; Bartlett NL; Rosenblatt JD; Kennedy DA; Younes A
    Oncologist; 2012; 17(8):1073-80. PubMed ID: 22855426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.
    Younes A; Gopal AK; Smith SE; Ansell SM; Rosenblatt JD; Savage KJ; Ramchandren R; Bartlett NL; Cheson BD; de Vos S; Forero-Torres A; Moskowitz CH; Connors JM; Engert A; Larsen EK; Kennedy DA; Sievers EL; Chen R
    J Clin Oncol; 2012 Jun; 30(18):2183-9. PubMed ID: 22454421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting CD30 Using Brentuximab Vedotin in the Treatment of Hodgkin Lymphoma.
    Alperovich A; Younes A
    Cancer J; 2016; 22(1):23-6. PubMed ID: 26841013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study.
    Younes A; Connors JM; Park SI; Fanale M; O'Meara MM; Hunder NN; Huebner D; Ansell SM
    Lancet Oncol; 2013 Dec; 14(13):1348-56. PubMed ID: 24239220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I / II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma.
    Ogura M; Tobinai K; Hatake K; Ishizawa K; Uike N; Uchida T; Suzuki T; Aoki T; Watanabe T; Maruyama D; Yokoyama M; Takubo T; Kagehara H; Matsushima T
    Cancer Sci; 2014 Jul; 105(7):840-6. PubMed ID: 24814862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey.
    Salihoglu A; Elverdi T; Karadogan I; Paydas S; Ozdemir E; Erdem G; Karadurmus N; Akyol G; Kaynar L; Yegin Z; Sucak G; Ozkocaman V; Topcuoglu P; Ozcan M; Birtas E; Goker H; Baslar Z; Ferhanoglu B
    Ann Hematol; 2015 Mar; 94(3):415-20. PubMed ID: 25231929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brentuximab vedotin: an anti-CD30 antibody-drug conjugate.
    Bradley AM; Devine M; DeRemer D
    Am J Health Syst Pharm; 2013 Apr; 70(7):589-97. PubMed ID: 23515511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma.
    Vaklavas C; Forero-Torres A
    Ther Adv Hematol; 2012 Aug; 3(4):209-25. PubMed ID: 23606932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma.
    Bhatt S; Ashlock BM; Natkunam Y; Sujoy V; Chapman JR; Ramos JC; Mesri EA; Lossos IS
    Blood; 2013 Aug; 122(7):1233-42. PubMed ID: 23838350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies.
    Han TH; Chen R; Advani R; Berryman RB; Smith SE; Forero-Torres A; Rosenblatt JD; Smith MR; Zain J; Hunder NN; Engert A
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):241-9. PubMed ID: 23719719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.